跳至主要内容
临床试验/EUCTR2020-001605-23-ES
EUCTR2020-001605-23-ES进行中(未招募)1 期

Effectiveness of the combined treatment with hydroxycloroquine and azithromycin vs lopinavir/ritonavir + hydroxycloroquine in hospitalized patients with confirmed COVID-19 infection

Basque Health Service0 个研究点目标入组 108 人开始时间: 2020年5月31日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
108

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - RT-PCR confirmed.
  • - 18-80 years.
  • - Pneumonia confirmed by Rx chest: pneumonia CURB<=1 y Sat O2>92%
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 60
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 68

排除标准

  • ->7 days from the onset of symptoms
  • - Severe disease Covid 19, defined by any of the following: FR<30 per min, sat O2 breathing ambient air<92%, sepsis or septic shock
  • - Pregnancy
  • - Kidney or liver terminal disease
  • - History of allergy to hydroxycloroquine and/or azithromycin
  • - Patients presenting contraindications to study drugs
  • - Hyprsensitivity to azithromycin, erythromycin, to any other macrolide or ketolide antibioticor any of the following excipients: pregelatinized corn starch, sodium crocarmellose, sodium laurel sulfate, magnesium stearate, anhydrous calcium hydrogen phosphate, hypromellose, titanium dioxide (E-171), triacetin.
  • - Electrocardiographic abnormalities: treatment is not started or discontinued if QTc (Brazett formula)>500ms and risk-benefit is valued between a460-500 ms. Does not start treatment if ECG shows changes in channel-patties and risk-benefit is valued if there are other abnormalities.
  • - Patients with glucose 6 phosphate dehydrogenase deficiency.

研究者

发起方
Basque Health Service

相似试验

Effectiveness of the combined treatment with... | 临床试验